Ethos Technologies Q3 net loss narrows as expenses fall
LIFE•Ethos Technologies reported zero revenue in Q3 as its net loss narrowed year over year and operating expenses fell to $18.79 million. It ended the quarter with $50.3 million in cash and expects its cash to fund operations into late 2028.
1. Quarterly results
Ethos Technologies reported zero revenue in Q3, while its net loss narrowed year over year. Operating expenses were $18.79 million, with lower research and development costs contributing to the decline.
2. Efzofitimod study plans
The company said it reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in pulmonary sarcoidosis and has initiated related activities. It plans to prioritize strategic partnerships or licensing to advance the study.
3. Cash outlook
Ethos Technologies ended Q3 with $50.3 million in cash and expects its cash position to fund operations into late 2028.
